| Truecandor Behavioral Health, Llc | |
|
6338 Us Highway 301 S Riverview FL 33578-3829 | |
| (813) 419-3386 | |
| (813) 793-4879 |
| Full Name | Truecandor Behavioral Health, Llc |
|---|---|
| Speciality | Counselor |
| Location | 6338 Us Highway 301 S, Riverview, Florida |
| Authorized Official Name and Position | Angela Corbett (OWNER) |
| Authorized Official Contact | 8134193386 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Truecandor Behavioral Health, Llc 1202 Florablu Dr Seffner FL 33584-3531 Ph: (813) 419-3386 | Truecandor Behavioral Health, Llc 6338 Us Highway 301 S Riverview FL 33578-3829 Ph: (813) 419-3386 |
| NPI Number | 1013524883 |
|---|---|
| Provider Enumeration Date | 09/25/2020 |
| Last Update Date | 03/06/2024 |
| Certification Date | 03/06/2024 |
| Medicare PECOS PAC ID | 9830504034 |
|---|---|
| Medicare Enrollment ID | O20210222001493 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013524883 | NPI | - | NPPES |
| 1134565245 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Provider Name | Meredith L Chrystie |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1649804675 PECOS PAC ID: 4587092820 Enrollment ID: I20200320001460 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Jennie K Gintoli |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1154814747 PECOS PAC ID: 2860819612 Enrollment ID: I20200825003597 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Angela L Corbett |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1134565245 PECOS PAC ID: 2567877764 Enrollment ID: I20210222001590 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Alisa Colleen Davis |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1184224784 PECOS PAC ID: 3678974482 Enrollment ID: I20210630004061 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Brittany Saricka Joseph |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1790266229 PECOS PAC ID: 8224420195 Enrollment ID: I20220126002773 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Ashley L Aplin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1093161267 PECOS PAC ID: 9931584935 Enrollment ID: I20220912001884 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Sara Sharp |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1255043592 PECOS PAC ID: 7911370218 Enrollment ID: I20230308000546 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Rachel Elzey |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1346875606 PECOS PAC ID: 1052785748 Enrollment ID: I20230320002995 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Francia Pierre |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1023485828 PECOS PAC ID: 4082070834 Enrollment ID: I20230519002285 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Justine Alemany |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1700228194 PECOS PAC ID: 4486010030 Enrollment ID: I20230524000345 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Patricia Hoyt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861276131 PECOS PAC ID: 1355797382 Enrollment ID: I20231027002062 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Kendal Hansen |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1184260069 PECOS PAC ID: 5890143960 Enrollment ID: I20231129003866 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
| Provider Name | Sarah Doan |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1528460920 PECOS PAC ID: 6406204494 Enrollment ID: I20231201000719 |
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
News Archive
Two existing definitions of chronic multisymptom illness (CMI) - one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans - should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine.
Professor John Mayer and Dr Simon Dawson, in collaboration with colleagues at Japan's Kyoto University, have discovered the function of a new liver oncoprotein - or cancer causing protein - which could be the first step to finding effective new treatments for the deadly illness.
VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.
Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.
› Verified 1 days ago
Pathway To Healing Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 13184 Us Highway 301 S Unit 13194, Riverview, FL 33578 Phone: 813-705-7098 | |
Aaron Keith Robinson Foundation, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7201 Forest Mere Dr, Riverview, FL 33578 Phone: 813-732-1180 | |
Adaska Therapy And Wellness Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 11525 Sunburst Marble Rd, Riverview, FL 33579 Phone: 813-252-0978 | |
Baycare Medical Group Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 10141 Big Bend Rd Ste 206, Riverview, FL 33578 Phone: 813-397-1274 | |
Tuff Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 11327 Brighton Knoll Loop, Riverview, FL 33579 Phone: 860-262-0625 | |
House Of Esther Group Home, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 9703 Bay Colony Dr, Riverview, FL 33578 Phone: 718-413-3982 |